Vivani Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $130.2M
- Price
- $1.51
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.14%
- Volume
- 321.1K
About
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Quick stats
Shares outstanding86.2M
Computed float39.3M
Float / shares45.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001266806
Websitehttps://www.vivani.com
AI Summary
AI-generated1/16
majorbullishearnings
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical reported Q2 financial results with a narrowed net loss of $6.4 million compared to $7.1 million in the prior year, ending the quarter with $20.8 million in cash.
Operationally, the company completed dosing in its Phase 1 SLIM-1 trial for the NPM-139 implant ahead of schedule and entered a non-exclusive evaluation agreement with Novo Nordisk.
Additionally, Vivani announced the pending merger of its subsidiary Cortigent with ClearOne, expected to close in Q3 2026, which will establish Cortigent as a separate public entity trading under ticker CRGT.
Red flags
- Limited cash runway of approximately 3 quarters based on current operating expense rate.
- Company remains pre-revenue with ongoing net losses.